The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

According to a recent study, glucagon-like peptide-1 receptor agonists are associated with a reduction in alcohol intake.

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

In fact, you may have gotten more than a few targeted ads on social media from telehealth platforms selling these cheaper GLP ...

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

Data-driven clustering reveals distinct obesity phenotypes with unique clinical, behavioral, microbiome features, and differential GLP-1 responses.